Cargando…
The role of booster vaccination in decreasing COVID-19 age-adjusted case fatality rate: Evidence from 32 countries
BACKGROUND: The global COVID-19 pandemic is still ongoing, and cross-country and cross-period variation in COVID-19 age-adjusted case fatality rates (CFRs) has not been clarified. Here, we aimed to identify the country-specific effects of booster vaccination and other features that may affect hetero...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151823/ https://www.ncbi.nlm.nih.gov/pubmed/37143970 http://dx.doi.org/10.3389/fpubh.2023.1150095 |
_version_ | 1785035624470806528 |
---|---|
author | Zhou, Cui Wheelock, Åsa M. Zhang, Chutian Ma, Jian Dong, Kaixing Pan, Jingxiang Li, Zhichao Liang, Wannian Gao, Jing Xu, Lei |
author_facet | Zhou, Cui Wheelock, Åsa M. Zhang, Chutian Ma, Jian Dong, Kaixing Pan, Jingxiang Li, Zhichao Liang, Wannian Gao, Jing Xu, Lei |
author_sort | Zhou, Cui |
collection | PubMed |
description | BACKGROUND: The global COVID-19 pandemic is still ongoing, and cross-country and cross-period variation in COVID-19 age-adjusted case fatality rates (CFRs) has not been clarified. Here, we aimed to identify the country-specific effects of booster vaccination and other features that may affect heterogeneity in age-adjusted CFRs with a worldwide scope, and to predict the benefit of increasing booster vaccination rate on future CFR. METHOD: Cross-temporal and cross-country variations in CFR were identified in 32 countries using the latest available database, with multi-feature (vaccination coverage, demographic characteristics, disease burden, behavioral risks, environmental risks, health services and trust) using Extreme Gradient Boosting (XGBoost) algorithm and SHapley Additive exPlanations (SHAP). After that, country-specific risk features that affect age-adjusted CFRs were identified. The benefit of booster on age-adjusted CFR was simulated by increasing booster vaccination by 1–30% in each country. RESULTS: Overall COVID-19 age-adjusted CFRs across 32 countries ranged from 110 deaths per 100,000 cases to 5,112 deaths per 100,000 cases from February 4, 2020 to Jan 31, 2022, which were divided into countries with age-adjusted CFRs higher than the crude CFRs and countries with age-adjusted CFRs lower than the crude CFRs (n = 9 and n = 23) when compared with the crude CFR. The effect of booster vaccination on age-adjusted CFRs becomes more important from Alpha to Omicron period (importance scores: 0.03–0.23). The Omicron period model showed that the key risk factors for countries with higher age-adjusted CFR than crude CFR are low GDP per capita and low booster vaccination rates, while the key risk factors for countries with higher age-adjusted CFR than crude CFR were high dietary risks and low physical activity. Increasing booster vaccination rates by 7% would reduce CFRs in all countries with age-adjusted CFRs higher than the crude CFRs. CONCLUSION: Booster vaccination still plays an important role in reducing age-adjusted CFRs, while there are multidimensional concurrent risk factors and precise joint intervention strategies and preparations based on country-specific risks are also essential. |
format | Online Article Text |
id | pubmed-10151823 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101518232023-05-03 The role of booster vaccination in decreasing COVID-19 age-adjusted case fatality rate: Evidence from 32 countries Zhou, Cui Wheelock, Åsa M. Zhang, Chutian Ma, Jian Dong, Kaixing Pan, Jingxiang Li, Zhichao Liang, Wannian Gao, Jing Xu, Lei Front Public Health Public Health BACKGROUND: The global COVID-19 pandemic is still ongoing, and cross-country and cross-period variation in COVID-19 age-adjusted case fatality rates (CFRs) has not been clarified. Here, we aimed to identify the country-specific effects of booster vaccination and other features that may affect heterogeneity in age-adjusted CFRs with a worldwide scope, and to predict the benefit of increasing booster vaccination rate on future CFR. METHOD: Cross-temporal and cross-country variations in CFR were identified in 32 countries using the latest available database, with multi-feature (vaccination coverage, demographic characteristics, disease burden, behavioral risks, environmental risks, health services and trust) using Extreme Gradient Boosting (XGBoost) algorithm and SHapley Additive exPlanations (SHAP). After that, country-specific risk features that affect age-adjusted CFRs were identified. The benefit of booster on age-adjusted CFR was simulated by increasing booster vaccination by 1–30% in each country. RESULTS: Overall COVID-19 age-adjusted CFRs across 32 countries ranged from 110 deaths per 100,000 cases to 5,112 deaths per 100,000 cases from February 4, 2020 to Jan 31, 2022, which were divided into countries with age-adjusted CFRs higher than the crude CFRs and countries with age-adjusted CFRs lower than the crude CFRs (n = 9 and n = 23) when compared with the crude CFR. The effect of booster vaccination on age-adjusted CFRs becomes more important from Alpha to Omicron period (importance scores: 0.03–0.23). The Omicron period model showed that the key risk factors for countries with higher age-adjusted CFR than crude CFR are low GDP per capita and low booster vaccination rates, while the key risk factors for countries with higher age-adjusted CFR than crude CFR were high dietary risks and low physical activity. Increasing booster vaccination rates by 7% would reduce CFRs in all countries with age-adjusted CFRs higher than the crude CFRs. CONCLUSION: Booster vaccination still plays an important role in reducing age-adjusted CFRs, while there are multidimensional concurrent risk factors and precise joint intervention strategies and preparations based on country-specific risks are also essential. Frontiers Media S.A. 2023-04-18 /pmc/articles/PMC10151823/ /pubmed/37143970 http://dx.doi.org/10.3389/fpubh.2023.1150095 Text en Copyright © 2023 Zhou, Wheelock, Zhang, Ma, Dong, Pan, Li, Liang, Gao and Xu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Public Health Zhou, Cui Wheelock, Åsa M. Zhang, Chutian Ma, Jian Dong, Kaixing Pan, Jingxiang Li, Zhichao Liang, Wannian Gao, Jing Xu, Lei The role of booster vaccination in decreasing COVID-19 age-adjusted case fatality rate: Evidence from 32 countries |
title | The role of booster vaccination in decreasing COVID-19 age-adjusted case fatality rate: Evidence from 32 countries |
title_full | The role of booster vaccination in decreasing COVID-19 age-adjusted case fatality rate: Evidence from 32 countries |
title_fullStr | The role of booster vaccination in decreasing COVID-19 age-adjusted case fatality rate: Evidence from 32 countries |
title_full_unstemmed | The role of booster vaccination in decreasing COVID-19 age-adjusted case fatality rate: Evidence from 32 countries |
title_short | The role of booster vaccination in decreasing COVID-19 age-adjusted case fatality rate: Evidence from 32 countries |
title_sort | role of booster vaccination in decreasing covid-19 age-adjusted case fatality rate: evidence from 32 countries |
topic | Public Health |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151823/ https://www.ncbi.nlm.nih.gov/pubmed/37143970 http://dx.doi.org/10.3389/fpubh.2023.1150095 |
work_keys_str_mv | AT zhoucui theroleofboostervaccinationindecreasingcovid19ageadjustedcasefatalityrateevidencefrom32countries AT wheelockasam theroleofboostervaccinationindecreasingcovid19ageadjustedcasefatalityrateevidencefrom32countries AT zhangchutian theroleofboostervaccinationindecreasingcovid19ageadjustedcasefatalityrateevidencefrom32countries AT majian theroleofboostervaccinationindecreasingcovid19ageadjustedcasefatalityrateevidencefrom32countries AT dongkaixing theroleofboostervaccinationindecreasingcovid19ageadjustedcasefatalityrateevidencefrom32countries AT panjingxiang theroleofboostervaccinationindecreasingcovid19ageadjustedcasefatalityrateevidencefrom32countries AT lizhichao theroleofboostervaccinationindecreasingcovid19ageadjustedcasefatalityrateevidencefrom32countries AT liangwannian theroleofboostervaccinationindecreasingcovid19ageadjustedcasefatalityrateevidencefrom32countries AT gaojing theroleofboostervaccinationindecreasingcovid19ageadjustedcasefatalityrateevidencefrom32countries AT xulei theroleofboostervaccinationindecreasingcovid19ageadjustedcasefatalityrateevidencefrom32countries AT zhoucui roleofboostervaccinationindecreasingcovid19ageadjustedcasefatalityrateevidencefrom32countries AT wheelockasam roleofboostervaccinationindecreasingcovid19ageadjustedcasefatalityrateevidencefrom32countries AT zhangchutian roleofboostervaccinationindecreasingcovid19ageadjustedcasefatalityrateevidencefrom32countries AT majian roleofboostervaccinationindecreasingcovid19ageadjustedcasefatalityrateevidencefrom32countries AT dongkaixing roleofboostervaccinationindecreasingcovid19ageadjustedcasefatalityrateevidencefrom32countries AT panjingxiang roleofboostervaccinationindecreasingcovid19ageadjustedcasefatalityrateevidencefrom32countries AT lizhichao roleofboostervaccinationindecreasingcovid19ageadjustedcasefatalityrateevidencefrom32countries AT liangwannian roleofboostervaccinationindecreasingcovid19ageadjustedcasefatalityrateevidencefrom32countries AT gaojing roleofboostervaccinationindecreasingcovid19ageadjustedcasefatalityrateevidencefrom32countries AT xulei roleofboostervaccinationindecreasingcovid19ageadjustedcasefatalityrateevidencefrom32countries |